99.14%
Lot
KES-202608-394
Purity
99.11%
- Form
- Lyophilised powder
- Storage
- −20 °C, desiccated
- Stability
- 24 months
- CAS
- 147732-56-7
- Formula
- C30H54N6O5
- Molecular weight
- 578.79 g/mol
- Solubility
- Ethanol first, then aqueous buffer. ≤5 mg/mL in water alone.
Palmitoyl Tripeptide-1
Matrikine, palmitoylated
£27
Vial massMATRIXYL3000-50-KES
1
91 vials in stock · dispatched within 24 h
A lipidated matrikine tripeptide. The palmitoyl chain confers the lipophilicity required for emulsion work; dissolve in a small volume of ethanol before aqueous dilution.
Dermal formulationCollagen I expression
Supplied for laboratory research use only. Not for human or veterinary use, consumption, or clinical application.
Analysis
Certificate of analysis
RP-HPLC chromatogramColmaric Analyticals
Retention time (min)λ 214 nm
Purity99.11%
Specification ≥ 98.0%
- Lot
- KES-202608-394
- Released
- 2026-08-14
- Mass expected
- 578.79 Da
- Mass found
- 578.60 Da
- Water (KF)
- 3.34%
- Endotoxin
- 0.052 EU/mg
- Appearance
- White lyophilisate
Primary structure
3 residues
Hover a residue for detail
- Formula
- C30H54N6O5
- Molecular weight
- 578.79 g/mol
Interactive
Reconstitution
Vial mass
mL
mcg
Syringe
- Draw to
- 1.0 units
- Volume
- 0.010 mL
- Concentration
- 25.00 mg/mL
- Draws per vial
- 200
Arithmetic for Palmitoyl Tripeptide-1 at the values you entered. Not a protocol and not a dose recommendation. Research use only.
Handling
- On arrival
- Transfer to −20 °C within two hours. Vials ship on phase-change packs rated for 72 hours.
- Reconstitution
- Ethanol first, then aqueous buffer. ≤5 mg/mL in water alone.
- After reconstitution
- 2–8 °C, use within 28 days. Aliquot to avoid freeze-thaw cycling.
- Shelf life
- 24 months lyophilised, desiccated and protected from light.